boehringer ingelheim glp-1 🚨 Survodutide, a weekly subcutaneous dual GLP-1/glucagon agonist, posts new top-line Phase 3 results today 📊 SYNCHRONIZE-1: Adults with overweight/obesity randomized to survodutide vs. placebo for 76 weeks ⚖️ 16.6% weight loss ( Weight loss drugs: Boehringer Ingelheim,

A: GLP-1 therapy is generally recommended for individuals who are obese (with a BMI of 30 or higher) or overweight (with a BMI of 27 or higher) with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol

Cardiac energy metabolism in heart failure

Alongside improvements in fasting glucose and weight maintenance, dapagliflozin was associated with a progressively greater shift in gut microbiota composition over time, particularly influencing taxa such as Lactobacillus and Muribaculaceae in a diabetic kidney disease mice model [36]

Surgeons need to start routinely measuring fat-soluble vitamins A, D, E, and K in weight-loss patients, because when they lose fat, they lose these vitamins

Florida Wellness & Medical Care offers medically supervised weight loss programs in Hollywood, FL, with personalized plans and medication options

Ramachandran plot for I-M-150845 using Mol Probity version 4.4 in Swiss-model protein structure homology modeling server